...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes - that is the amazing part of HDVY - it has so many POTENTIAL paths to follow.
A Large company can just scoop up HDVY for its multiple patents and potential applications.
MORE and more big companies are doing this. FAR easier to buy out these gems and take a leap in new industries.
PAR is a trend. Cloud computing, data mining are the wave of the future...
Catch the wave!
Cheers
Yes - additional source of revenue - and will show up in the future.
Health Discovery Corporation Announces Strategic Partnership with Adaptive, Inc.
Last update: 9/1/2010 9:27:00 AM
SAVANNAH, Ga., Sep 01, 2010 (BUSINESS WIRE) -- Health Discovery Corporation (HDVY) is pleased to announce a strategic partnership with Adaptive, Inc., a market leader in helping international companies and government agencies to capture, organize and manage the data they create. Founded in 2002, Adaptive is a transatlantic company with its U.S. Headquarters in Aliso Viejo, California.
Companies today are faced with an explosion of the amount, complexity and importance of enterprise data. Enabling the ability to capture, analyze and manage this data is of critical importance for their business success. Adaptive has developed and sells its leading data management technology to large, complex corporations around the world.
"Adaptive has been very successful in assisting large international corporations and government agencies collect, store and manage their data in a single sophisticated database," said Jeff Goins, Adaptive's President. "Now our large global customers want to identify patterns in their newly organized data which can greatly add to the success of their business. As such, we are really excited to partner with Health Discovery Corporation, a company which has a superior pattern-recognition technology called Support Vector Machines, an award winning patent portfolio protecting their technology, and world-class mathematicians to assist our customers in their effort to generate additional significant revenues and cost savings by identifying unique patterns in their complex databases."
According to Jeff Goins, Adaptive's President, "Health Discovery Corporation's technology can play a pivotal role in identifying patterns in electronic health records management, health care insurance, fraud detection (especially in the Medicaid/Medicare system), banking, customer data management, marketing, risk management and homeland security which represent a sampling of Adaptive's current customer base."
"Enormous amounts of data are being created every second of every day and companies and governmental agencies need to run sophisticated pattern recognition analysis on their data to generate additional revenue sources, as well as, cost savings opportunities," said Stephen D. Barnhill, Chairman and CEO, Health Discovery Corporation. "I see significant revenue potential for Health Discovery Corporation by applying our patented, pattern recognition technology in the area of data management and data-mining for these large international companies and government agencies which are customers of Adaptive Inc.," said Dr. Barnhill.
"The critical first step in achieving this goal is getting structured and unstructured data well organized and prepared for the successful application of our pattern-recognition technology and that's what Adaptive does so well," said Dr. Barnhill. "The combination of creating well structured data and then applying pattern-recognition analysis to that data is a winning strategy."
A 2005 report by IBM (IBM) titled, "Managing data in the 21st century," states: "Costs associated with managing and storing the burgeoning amount of enterprise wide data continue to expand exponentially. Now, more than ever, companies need to analyze their ability to backup, recover and manage that data--which is now the key business asset."
A July 2010 Wall Street Journal article titled, "Big Data, Big Growth, Big M&A," stated: "The big data problem is getting bigger. Every enterprise data center vendor, from Oracle Corp. (NasdaqGS: ORCL) to Hewlett Packard Co. (HPQ) sees an opportunity in solving it."
About Health Discovery Corporation
Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see .
About Adaptive, Inc.
Founded in 2002, Adaptive is a transatlantic company with its U.S. headquarters in Aliso Viejo, California.
Adaptive's mission is to help complex organizations adapt and support the rapidly changing IT and business environments which are driven by the ever increasing demands of compliance, regulatory pressures and governance requirements. Adaptive enables companies faced with an explosion of the amount, complexity and importance of enterprise metadata to capture, analyze and manage this metadata on a single point of truth platform. Adaptive has developed and delivers its leading semantic metadata repository technology to large, complex organizations around the world.
Adaptive has developed and delivered a single, automated framework, The Adaptive Framework, for capturing, storing, integrating, analyzing, visualizing and sharing the knowledge about an organization's strategies, processes, semantics, stewardship, technology and other resources. Adaptive's fundamental object-oriented design and standards based openness ensures agility in response to business requirement change. Its web-based accessibility leveraging its advanced workflow capability ensures a global platform for knowledge-sharing and better decision-making. With compliance to industry standards, the Adaptive offerings leverages existing data sources to include business intelligence, legacy, databases, ETL and various semantic modeling technologies and links the semantic relationships between these silo data sources enabling enterprises a platform for proper data governance, stewardship and change management.
Adaptive's current clients include major financial and insurance institutions, as well as federal and foreign government agencies.
Agree with you.
Again, this stock is something that is put away in an account and watch it grow. It is not a trading stock.
Patience will pay us all.
This letter reiterates most facts and is an upbeat confirmation on what's ahead. It is good that the little company is debt free and has an excellent amount of cash at hand.
I do not anticipate any significant "events" for another 6 months. Abbott & Quest appear to be taking their own time!
IF this drops to .09-.10 - I will continue to accumulate.
Cheers.
Hi Chazzy - that's my expectation as well! A relatively low float such as ours will easily get locked once the (news) message gets through and the investment funds start buying in - until then we wait.
Cheers.
Yes - and the vaccine is for those in ADVANCED stages of the cancer and is supposed give them 4 months of survival!
While our tests actually help SAVE lives by taking pre-emptive action in the early stages.
Cheers
DNDN - FDA approves its prostate cancer vaccine - Provenge!
One of these days ... this one will "wake up"!
Thank you --> tryn2makamil!
I really appreciate your sharing of this information with all of us.
Cheers.
GM Bob - hope you are keeping well.
I won't expect much action on this ticker for a while.
We are vulnerable at these price levels. Hopefully the ticker will not move down with today's market!
Let's see how she holds up.
Cheers.
Yes it does indeed. It captures very well the human part of the trading framework.
Thanks for posting that - a good reminder to keep things in perspective - and how the emotions/feelings affect our decisions to buy/sell.
Holding long here ... like most of us.
Cheers.
I am continuing to accumulate!
Cheers.
MM's job is to mess with us!
Trust your trading instincts - as you have done so.
Chart looks fine to me for accumulation at these levels.
I find that it is difficult to buy at the bid when the PPS drops as MMs are generally reluctant to sell it to you at the lower prices. I usually buy it in a small range.
We are all waiting for the Quest news to show up - since there is no news at this time, MMs are just booking their profits by bringing the price down.
I am adding at these levels.
Yes it is painful to see it slide.
I believe in this company and its core assets.
Cheers.
Good find "Bio-gold" - please do let us know what happened IF you are able to attend that seminar.
Cheers
Yes - numbers. Need the monthly cash flow to keep this growing.
Until they announce the Quest results of prostate test (which all of us are waiting for a while) - looks like this is going nowhere for now.
I will continue to hold.
Cheers.
Hey dollardaze - get away from the computer ... and enjoy your vacation!
Have a good time.
Thanks for posting that bruno.
Yes - it does seem frustrating - when there are so many "funny" companies which show no real value but their PPS goes up like a rocket.
Our time will come when the monthly cash flow starts rolling in.
Yes - I cannot emphasize strongly how big this little company will grow into - because of the many explosive strategies it has going for it - if we have the patience to hold onto it.
Cheers
Don't forget to order their product - for those that need it.
It simply works!
They have a very nice deal going on that will expire tomorrow.
2 for the price of 1 - before they go on the regional and national campaign.
Chart looked ready yesterday for a pop - let's see how high they can get this! IF we get this over .28-.30 - that will be nice.
Again, this is not a daytrade - you will need to hold onto this!
Like many other longtimers here, I am holding for double digits.
Cheers
Yes - great news - another arrow in our quiver.
Yes - I would conclude that HDVY has already issued this - and that might explain why the price appears to be held down.
I would think that step is already finished.
Form 8-K for HEALTH DISCOVERY CORP
17-Mar-2010
Entry into a Material Definitive Agreement, Unregistered Sale of Equity Sec
Item 1.01 Entry into a Material Definitive Agreement.
On March 11, 2010, Health Discovery Corporation ("HDC"), Smart Personalized Medicine, LLC ("SPM") and Quest Diagnostics Incorporated ("Quest") entered into a Development Agreement (the "Quest Development Agreement") pursuant to which HDC and SPM will assist Quest in the development of new laboratory tests for aiding in the selection of breast cancer therapies. HDC, SPM and Quest also entered a related Licensing Agreement (the "Quest License").
Pursuant to the Quest License, SPM granted a co-exclusive (with SPM) sublicense to utilize the Licensed Patent Rights to the extent necessary to enable Quest to develop Products and perform the Validation Work under the Quest Development Agreement. Quest has the right to use SPM's Breast Cancer Database, including biopsies and access to a database of clinical and genomic information on breast cancer patients it has previously licensed (the "Database").
In consideration for the license, Quest will separately make payments to HDC and SPM. Such payments to HDC will include a $500,000 up front "Development License Fee," monthly "License Maintenance Fees" equal to $8,750 for the first year and $17,500 for each year thereafter (with such fees being credited against the "Royalty Payments" described below), upon the publication of a study performed for the Validation Work an "Initial Product License Fee" of $125,000 for each of the first two Products, and "Royalty Payments" equal to 2.45% of the Net Sales of each Licensed Product (i.e., each breast cancer test) sold by Quest. Quest will reimburse SPM and HDC for costs incurred related to any Validation Work done with respect to a Product.
Pursuant to the Quest Development Agreement, HDC is required to use its support vector machine technology and other intellectual property licensed to SPM to analyze data for the development and/or validation of applications of clinical laboratory services, In Vitro Diagnostic kits, clinical trial services and the other elements of "Field" (collectively, the "Products").
In consideration for HDC's efforts under the Quest Development Agreement, Quest will pay HDC $375,000 (in addition to the $500,000 described above), which payments shall be made monthly over the next nine months.
Effective March 11, 2010, HDC and SPM amended (the "Amendment") the original License Agreement, dated August 22, 2008 (the "SPM License Agreement"), pursuant to which HDC had licensed its intellectual property to SPM for use in the development of breast cancer products. As amended, HDC will receive all payments under the Quest Development Agreement and License Agreement directly from Quest, and SPM will not be required to make any additional payments to the Company related to either such agreement. In addition, HDC's equity percentage interest in SPM was increased from 15% to 20%, and such equity percentage interest may be diluted only to the same extent and in the same manner as each other initial equity percentage interest holder; provided, however, that when raising additional equity, SPM must obtain HDC's prior written approval of the terms and conditions of such equity offering.
Item 3.02. Unregistered Sales of Equity Securities.
Since the filing of the Company's Form 8-K on February 18, 2010, the Company issued 11,729,388 shares of its common stock, no par value ("Common Stock"), pursuant to the exercise of previously issued warrants to acquire such shares of Common Stock. The Company received a total of $2,228,584 as a result of the exercise of the warrants. All shares of Common Stock were issued in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act of 1933, as amended, and Regulation D promulgated thereunder.
Health Discovery Corporation and Smart Personalized Medicine Form Agreement for Developing Laboratory Tests for Breast Cancer Therapy Selection with Quest Diagnostics
SAVANNAH, Ga. & MILFORD, Del.--(BUSINESS WIRE)--Health Discovery Corporation (OTCBB: HDVY - News) (HDC) and Smart Personalized Medicine, LLC (SPM) announced today that they have entered into development and related licensing agreements with Quest Diagnostics Incorporated (NYSE: DGX - News), the world’s leading provider of diagnostic testing, information and services. Under the agreements, Quest Diagnostics will develop new laboratory tests for aiding in the selection of breast cancer therapies.
Under the terms of the agreements, HDC and SPM will receive upfront licensing payments, development fees and royalties on a per test basis from Quest Diagnostics.
In February 2009, Health Discovery Corporation announced that it had licensed rights to develop a new urine-based test for clinically significant prostate cancer to Quest Diagnostics.
About Health Discovery Corporation
Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com.
About Smart Personalized Medicine, LLC
Smart Personalized Medicine, LLC was formed by Richard E. Caruso, Ph.D., to focus on and enable the development of a new methodology of accomplishing detailed breast cancer patient diagnosis and personalized individual treatment. In 2006, Caruso was named the E&Y National Entrepreneur of the Year for the United States following of his founding of Integra LifeSciences Corporation (NasdaqGS: IART - News). Health Discovery Corporation owns an equity position in Smart Personalized Medicine.
Chart looks ready ... let's go through the .28 ceiling with volume...
heh heh ... catch the wave!
The quiet period before the storm ...
Staying LONG.
Cheers.
Great perspective "Steady_T".
The many "irons in the fire" that this company has will surely stoke this stock.
Cheers
A close just above .30 will wrap up a great week for HDVY ... wishful thinking ... another 25 minutes to go.
Growth with monthly cash flow for HDVY!
The PPS I hope would be a little more explosive than BRKR's steady chart :) - with periodic jumps.
That would be my expectation from HDVY as the months go by!
Will dream on it this weekend ... lol
Bullish overall market day today ... big blocks going through now for this company.
Saw that earlier - but will no longer post any information from him.
I have him on "ignore".
That's a good one ... lol
hmmm... I only see 284k at 1:09 - the rest are chunks at various times between 1:09 and 1:12.
Yes ... we are getting momentum. Good volume.
Might close at .30 (heh heh TSBob!)
2010 will be the year for you Degreed! Your patience will reward you well.
Yes! There are so many types of cancers. HDVY will go after all of them using their crown jewel SVM technology. One by one, they will isolate the biomarkers and partner with the best partner(s) to generate the crucial periodic cash flow for each test done.
I expect to hear news about these partnerships this year!
The market is bullish today - let's see how this helps HDVY maintain its momentum today.